Completed NA INTERVENTIONAL NCT00002290

The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection

A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection

Sponsor: Glaxo Wellcome

Conditions HIV Infections

Interventions Acyclovir Zidovudine

Updated 6 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on HIV Infections, this trial is completed. The trial is conducted by Glaxo Wellcome and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glaxo Wellcome

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bay Pines, United States , Birmingham, United States , Charlottesville, United States , Chicago, United States , Detroit, United States , Galveston, United States , Houston, United States , Nashville, United States , Philadelphia, United States , Richmond, United States and 4 more locations